Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology & Inflammation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PIK3CG drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase (WT) | PIK3CG Kinase Domain, high purity (>95%), Endotoxin <1EU/µg, Sequence Verified, HEK293 expressed. | View PIK3CG Products |
| Mutant / Resistance Panel | Mutant proteins covering key activation loop and drug-binding pocket variants (e.g., Cys, Gatekeeper) for resistance mechanism studies. | View PIK3CG Products |
| Gene Delivery | PIK3CG Promise-ORF / Lentivirus, full-length ORF for stable cell lines. | View PIK3CG Products |
| Benchmark Ab | Anti-PIK3CG recombinant reference antibody, sequence-verified positive control for target engagement assays (WB, IP). | View PIK3CG Products |
| Validator | PIK3CG siRNA Set for isoform-specific knockdown verification. | View PIK3CG Products |
| PIK3CA (p110α) | Oncogenic isoform; essential for selectivity counter-screening (toxicity avoidance). | View PIK3CA Products |
| PIK3CD (p110δ) | Hematologic isoform; often co-targeted with PIK3CG in lymphoma. | View PIK3CD Products |
| PTEN | Negative pathway regulator; for pathway validation and synthetic lethality studies. | View PTEN Products |
| PDCD1 (PD-1) | Synergistic target; PI3Kγ inhibition reprograms TAMs to enhance anti-PD-1 efficacy. | View PDCD1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform selectivity (γ vs α/β/δ) | PI3K Class I panel proteins (Human, HEK293 expressed) with >95% purity, sequence verified by Mass Spec. |
| Active vs inactive conformation screening | Phosphomimetic & dead-kinase mutants available for state-specific inhibitor screening. |
| Drug resistance profiling | Cys-space mutants & gatekeeper variants covering ATP-binding pocket and activation loop. |
| Cellular context validation | High-titer lentivirus for stable expression in macrophage/myeloid cell lines. |
| False positives in phenotypic assays | Validated siRNA included for target-specificity checks. |
| Lack of pathway controls | Sequence-verified wild-type and reference mutant proteins included. |
Live PIK3CG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
PIK3CG (p110γ) is the catalytic subunit of class IB PI3K, characterized by functional domains PI3K-ABD, PI3K-RBD, and C2 PI3K-type. It is predominantly expressed in hematopoietic cells and plays a central role in GPCR downstream signaling. Loss-of-function mutations (e.g., IMD97-associated variants) impair T-cell activation and lipid kinase activity, underscoring its role in immune regulation. The race for PIK3CG therapeutics is intensifying, with major players shifting focus from pan-PI3K inhibitors to isoform-selective strategies targeting the tumor microenvironment (TME). As first-generation γ-selective inhibitors (e.g., IPI-549 / Eganelisib, Infinity Pharma) advance through Phase II combination trials with checkpoint inhibitors, the next wave of R&D is targeting resistance mutations, dual γ/δ blockade for hematologic malignancies, allosteric inhibitors for inflammatory diseases, and PROTAC degraders for refractory solid tumors. Clinical momentum is building around myeloid cell reprogramming in solid tumors and inflammatory indications, positioning PIK3CG as a pivotal immuno-oncology target.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (γ-selective) | Infinity Pharma, AstraZeneca, Rhizen | Solid Tumors, TME modulation | Isoform Selectivity Panel (γ vs α/β/δ) with WT & Mutant Proteins |
| Dual γ/δ Inhibitors | TG Therapeutics, Genentech | Hematologic Malignancies (CLL, NHL) | Dual Homolog Panel for affinity ranking |
| Allosteric Inhibitors | Emerging Biotech | Inflammatory Disease | Active/Inactive Conformational Mutants for mechanism validation |
| Targeted Protein Degrader (PROTAC) | Preclinical Biotech Innovators | Refractory Solid Tumors | Ternary Complex Validation (High-Purity PIK3CG & E3 Ligases) |
| Combination (PI3Kγ + CPI) | Multiple Academia/Industry | Immunotherapy-resistant Cancers (e.g., TNBC, melanoma) | Stable Cell Line Lentivirus for immune cell co-culture assays |